Meta-analysis of randomized trials: GLP1 receptor agonists increase the risk of gallbladder and biliary diseases (RR, 1.37; 95% CI, 1.23-1.52).

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials – JAMA Internal Medicine (free for a limited period)

Commentary: GLP-1 Receptor Agonists: How Safe Are They for the Gallbladder?— Link with gallbladder, biliary diseases could be due to weight loss associated with class of drug – MedPage Today (free registration required)